Anosmia - A Clinical Review

Sanne Boesveldt, Elbrich M. Postma, Duncan Boak, Antje Welge-Luessen, Veronika Schöpf, Joel D. Mainland, Jeffrey Martens, John Ngai, Valerie B. Duffy

Research output: Contribution to journalReview articleAcademicpeer-review

19 Citations (Scopus)

Abstract

Anosmia and hyposmia, the inability or decreased ability to smell, is estimated to afflict 3-20% of the population. Risk of olfactory dysfunction increases with old age and may also result from chronic sinonasal diseases, severe head trauma, and upper respiratory infections, or neurodegenerative diseases. These disorders impair the ability to sense warning odors in foods and the environment, as well as hinder the quality of life related to social interactions, eating, and feelings of well-being. This article reports and extends on a clinical update commencing at the 2016 Association for Chemoreception Sciences annual meeting. Included were reports from: a patient perspective on losing the sense of smell with information on Fifth Sense, a nonprofit advocacy organization for patients with olfactory disorders; an otolaryngologist's review of clinical evaluation, diagnosis, and management/treatment of anosmia; and researchers' review of recent advances in potential anosmia treatments from fundamental science, in animal, cellular, or genetic models. As limited evidence-based treatments exist for anosmia, dissemination of information on anosmia-related health risks is needed. This could include feasible and useful screening measures for olfactory dysfunction, appropriate clinical evaluation, and patient counseling to avoid harm as well as manage health and quality of life with anosmia.

LanguageEnglish
Pages513-523
JournalChemical Senses
Volume42
Issue number7
DOIs
Publication statusPublished - 2017

Fingerprint

Olfaction Disorders
Aptitude
Smell
Quality of Life
Nonprofit Organizations
Patient Advocacy
Information Dissemination
Genetic Models
Health
Interpersonal Relations
Craniocerebral Trauma
Respiratory Tract Infections
Neurodegenerative Diseases
Counseling
Emotions
Chronic Disease
Therapeutics
Animal Models
Eating
Research Personnel

Keywords

  • genetics
  • neural reorganization
  • olfactory dysfunction
  • quality of life
  • stem cell regeneration
  • treatment

Cite this

Boesveldt, S., Postma, E. M., Boak, D., Welge-Luessen, A., Schöpf, V., Mainland, J. D., ... Duffy, V. B. (2017). Anosmia - A Clinical Review. Chemical Senses, 42(7), 513-523. https://doi.org/10.1093/chemse/bjx025
Boesveldt, Sanne ; Postma, Elbrich M. ; Boak, Duncan ; Welge-Luessen, Antje ; Schöpf, Veronika ; Mainland, Joel D. ; Martens, Jeffrey ; Ngai, John ; Duffy, Valerie B. / Anosmia - A Clinical Review. In: Chemical Senses. 2017 ; Vol. 42, No. 7. pp. 513-523.
@article{270dbbf0c3dc4c75bb85a0c34cdf1b75,
title = "Anosmia - A Clinical Review",
abstract = "Anosmia and hyposmia, the inability or decreased ability to smell, is estimated to afflict 3-20{\%} of the population. Risk of olfactory dysfunction increases with old age and may also result from chronic sinonasal diseases, severe head trauma, and upper respiratory infections, or neurodegenerative diseases. These disorders impair the ability to sense warning odors in foods and the environment, as well as hinder the quality of life related to social interactions, eating, and feelings of well-being. This article reports and extends on a clinical update commencing at the 2016 Association for Chemoreception Sciences annual meeting. Included were reports from: a patient perspective on losing the sense of smell with information on Fifth Sense, a nonprofit advocacy organization for patients with olfactory disorders; an otolaryngologist's review of clinical evaluation, diagnosis, and management/treatment of anosmia; and researchers' review of recent advances in potential anosmia treatments from fundamental science, in animal, cellular, or genetic models. As limited evidence-based treatments exist for anosmia, dissemination of information on anosmia-related health risks is needed. This could include feasible and useful screening measures for olfactory dysfunction, appropriate clinical evaluation, and patient counseling to avoid harm as well as manage health and quality of life with anosmia.",
keywords = "genetics, neural reorganization, olfactory dysfunction, quality of life, stem cell regeneration, treatment",
author = "Sanne Boesveldt and Postma, {Elbrich M.} and Duncan Boak and Antje Welge-Luessen and Veronika Sch{\"o}pf and Mainland, {Joel D.} and Jeffrey Martens and John Ngai and Duffy, {Valerie B.}",
year = "2017",
doi = "10.1093/chemse/bjx025",
language = "English",
volume = "42",
pages = "513--523",
journal = "Chemical Senses",
issn = "0379-864X",
publisher = "Oxford University Press",
number = "7",

}

Boesveldt, S, Postma, EM, Boak, D, Welge-Luessen, A, Schöpf, V, Mainland, JD, Martens, J, Ngai, J & Duffy, VB 2017, 'Anosmia - A Clinical Review', Chemical Senses, vol. 42, no. 7, pp. 513-523. https://doi.org/10.1093/chemse/bjx025

Anosmia - A Clinical Review. / Boesveldt, Sanne; Postma, Elbrich M.; Boak, Duncan; Welge-Luessen, Antje; Schöpf, Veronika; Mainland, Joel D.; Martens, Jeffrey; Ngai, John; Duffy, Valerie B.

In: Chemical Senses, Vol. 42, No. 7, 2017, p. 513-523.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Anosmia - A Clinical Review

AU - Boesveldt, Sanne

AU - Postma, Elbrich M.

AU - Boak, Duncan

AU - Welge-Luessen, Antje

AU - Schöpf, Veronika

AU - Mainland, Joel D.

AU - Martens, Jeffrey

AU - Ngai, John

AU - Duffy, Valerie B.

PY - 2017

Y1 - 2017

N2 - Anosmia and hyposmia, the inability or decreased ability to smell, is estimated to afflict 3-20% of the population. Risk of olfactory dysfunction increases with old age and may also result from chronic sinonasal diseases, severe head trauma, and upper respiratory infections, or neurodegenerative diseases. These disorders impair the ability to sense warning odors in foods and the environment, as well as hinder the quality of life related to social interactions, eating, and feelings of well-being. This article reports and extends on a clinical update commencing at the 2016 Association for Chemoreception Sciences annual meeting. Included were reports from: a patient perspective on losing the sense of smell with information on Fifth Sense, a nonprofit advocacy organization for patients with olfactory disorders; an otolaryngologist's review of clinical evaluation, diagnosis, and management/treatment of anosmia; and researchers' review of recent advances in potential anosmia treatments from fundamental science, in animal, cellular, or genetic models. As limited evidence-based treatments exist for anosmia, dissemination of information on anosmia-related health risks is needed. This could include feasible and useful screening measures for olfactory dysfunction, appropriate clinical evaluation, and patient counseling to avoid harm as well as manage health and quality of life with anosmia.

AB - Anosmia and hyposmia, the inability or decreased ability to smell, is estimated to afflict 3-20% of the population. Risk of olfactory dysfunction increases with old age and may also result from chronic sinonasal diseases, severe head trauma, and upper respiratory infections, or neurodegenerative diseases. These disorders impair the ability to sense warning odors in foods and the environment, as well as hinder the quality of life related to social interactions, eating, and feelings of well-being. This article reports and extends on a clinical update commencing at the 2016 Association for Chemoreception Sciences annual meeting. Included were reports from: a patient perspective on losing the sense of smell with information on Fifth Sense, a nonprofit advocacy organization for patients with olfactory disorders; an otolaryngologist's review of clinical evaluation, diagnosis, and management/treatment of anosmia; and researchers' review of recent advances in potential anosmia treatments from fundamental science, in animal, cellular, or genetic models. As limited evidence-based treatments exist for anosmia, dissemination of information on anosmia-related health risks is needed. This could include feasible and useful screening measures for olfactory dysfunction, appropriate clinical evaluation, and patient counseling to avoid harm as well as manage health and quality of life with anosmia.

KW - genetics

KW - neural reorganization

KW - olfactory dysfunction

KW - quality of life

KW - stem cell regeneration

KW - treatment

U2 - 10.1093/chemse/bjx025

DO - 10.1093/chemse/bjx025

M3 - Review article

VL - 42

SP - 513

EP - 523

JO - Chemical Senses

T2 - Chemical Senses

JF - Chemical Senses

SN - 0379-864X

IS - 7

ER -

Boesveldt S, Postma EM, Boak D, Welge-Luessen A, Schöpf V, Mainland JD et al. Anosmia - A Clinical Review. Chemical Senses. 2017;42(7):513-523. https://doi.org/10.1093/chemse/bjx025